The latest research study “Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” by IMARC Group, finds that the global monoclonal antibodies market size reached US$ 207.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 307.8 Billion by 2028, exhibiting a growth rate (CAGR) of 6.9% during 2023-2028.
Monoclonal antibodies (mAbs) represent laboratory-produced proteins used to serve as substitute antibodies that can modify, restore, enhance, and mimic the attack of the immune system on unwanted cells. They are utilized for targeting and detecting cancer cells for destruction by improving the immune system. In addition to this, monoclonal antibodies are used to block the connection between a cancer cell and proteins that promote cell growth. Furthermore, they prevent the formation of proteins to enable immune system cells to work efficiently against cancer cells. As such, mAbs transport the radiation treatment directly to cancer cells and reduce the effect of radiation on healthy cells.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/monoclonal-antibodies-market/requestsample
Monoclonal Antibodies Market Trends and Drivers:
The increasing prevalence of chronic ailments, such as heart disease, cancer, stroke, diabetes, arthritis, etc., is primarily driving the monoclonal antibodies market. Additionally, the escalating demand for humanized mAbs to treat several antigens, such as immunosuppression, cancer cells, immunomodulatory molecules, etc., is further catalyzing the market growth. Besides this, the widespread adoption of advanced genetic engineering technology in monoclonal antibodies production and the expanding healthcare industry are acting as significant growth-inducing factors. Moreover, the leading manufacturers are extensively investing in R&D activities to introduce enhanced mAb drugs for treating neurodegenerative diseases, including Alzheimer’s, Huntington’s, Parkinson’s, etc., and focusing on various marketing strategies, which is also positively influencing the global market. Apart from this, continuous technological advancements in numerous genetic platforms, such as next-generation sequencing, and the inflating need for cost-efficient biosimilar mAbs are anticipated to fuel the monoclonal antibodies market over the forecasted period.
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/monoclonal-antibodies-market
Monoclonal Antibodies Market Report Segmentation 2023-2028:
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
AbbVie Inc., Amgen Inc., Biogen Inc., F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Thermo Fisher Scientific Inc.
The report has been segmented the market into following categories:
Breakup by Production Method:
- In Vivo
- In Vitro
Breakup by Source:
- Murine
- Chimeric
- Humanized
- Human
Breakup by Indication:
- Cancer
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
- Others
Breakup by End Use:
- Hospitals
- Research Institutes
- Others
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Key highlights of the report:
- Market Performance (2017-2022)
- Market Outlook (2023- 2028)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
